These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8635827)

  • 41. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
    Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
    El-Beshlawy AM; El-Alfy MS; Sari TT; Chan LL; Tricta F
    Eur J Haematol; 2014 Apr; 92(4):337-40. PubMed ID: 24330079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.
    Vlachaki E; Tselios K; Perifanis V; Tsatra I; Tsayas I
    Clin Rheumatol; 2008 Nov; 27(11):1459-61. PubMed ID: 18663554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deferiprone: agranulocytosis and neurological disorders.
    Prescrire Int; 2007 Apr; 16(88):72. PubMed ID: 17460851
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.
    Pootrakul P; Sirankapracha P; Sankote J; Kachintorn U; Maungsub W; Sriphen K; Thakernpol K; Atisuk K; Fucharoen S; Chantraluksri U; Shalev O; Hoffbrand AV
    Br J Haematol; 2003 Jul; 122(2):305-10. PubMed ID: 12846901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of oral iron chelator deferiprone in young thalassaemics.
    Naithani R; Chandra J; Sharma S
    Eur J Haematol; 2005 Mar; 74(3):217-20. PubMed ID: 15693791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
    Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major.
    Bartakke S; Bavdekar SB; Kondurkar P; Muranjan MN; Manglani MV; Sharma R
    Indian Pediatr; 2005 Feb; 42(2):150-4. PubMed ID: 15767711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major.
    Goel H; Girisha KM; Phadke SR
    Hematology; 2008 Apr; 13(2):77-82. PubMed ID: 18616872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.
    Pati HP; Choudhry VP
    Eur J Haematol; 1999 Oct; 63(4):267-8. PubMed ID: 10530416
    [No Abstract]   [Full Text] [Related]  

  • 57. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
    Sheikh-Taha M; Koussa S; Inati A; Taher A
    Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral deferiprone--controversies on its efficacy and safety.
    Choudhry VP
    Indian J Pediatr; 1998; 65(6):825-8. PubMed ID: 10773946
    [No Abstract]   [Full Text] [Related]  

  • 59. Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study.
    Bansal D; Venkateshwaran S; Khandelwal N; Marwaha RK
    Pediatr Blood Cancer; 2011 Mar; 56(3):409-12. PubMed ID: 21113944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurological Complications and Cataract in a Child With Thalassemia Major Treated With Deferiprone.
    Parakh N; Sharma R; Prakash O; Mahto D; Dhingra B; Sharma S; Chandra J
    J Pediatr Hematol Oncol; 2015 Oct; 37(7):e433-4. PubMed ID: 26165407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.